Baskova I P, Paskhina T S, Poliantseva L R, Iakubovskaia R I, Tiero A
Vopr Med Khim. 1983 Sep-Oct;29(5):96-9.
A distinct increase of kallikrein content in blood plasma of patients with nephrotic syndrome as well as activation of thrombin simultaneously with a decrease in the prothrombin level were recorded in samples with synthetic chromogenic substrates S-2160 (Bz-Phe-Val-Arg-pNa), S-2238 (D-Phe-Pip-Arg-pNA) and S-2302 (D-Pro-Phe-Arg-pNA). Limited proteolysis of prothrombin by blood plasma kallikrein appears to be among the possible reasons of thrombin activation in the patients with nephrotic syndrome. Activity of plasmin, measured with S-2251 (D-Val-Leu-Lys-pNA) as a chromogenic substrate, was practically unlatered in blood plasma of these patients.
在使用合成显色底物S - 2160(苄氧羰基 - 苯丙氨酸 - 缬氨酸 - 精氨酸 - 对硝基苯胺)、S - 2238(D - 苯丙氨酸 - 哌啶 - 精氨酸 - 对硝基苯胺)和S - 2302(D - 脯氨酸 - 苯丙氨酸 - 精氨酸 - 对硝基苯胺)的样本中,记录到肾病综合征患者血浆中激肽释放酶含量明显增加,同时凝血酶激活,而凝血酶原水平降低。血浆激肽释放酶对凝血酶原的有限蛋白水解似乎是肾病综合征患者凝血酶激活的可能原因之一。以S - 2251(D - 缬氨酸 - 亮氨酸 - 赖氨酸 - 对硝基苯胺)作为显色底物测量的纤溶酶活性,在这些患者的血浆中实际上未发生变化。